LGNDZ — LIGAND PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 886163 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 51,812,000 | 43,554,000 | 3,143,000 | -7,172,000 | 941,774,000 | 72,307,000 | 111,335,000 |
| Dec 2023 | 32,868,000 | 24,630,000 | 3,078,000 | -10,273,000 | 787,216,000 | 22,954,000 | 86,303,000 |
| Dec 2022 | 59,221,000 | 50,653,000 | 12,341,000 | 404,000 | 762,668,000 | 45,006,000 | 165,183,000 |
| Dec 2021 | 64,835,000 | 53,008,000 | 15,706,000 | 13,723,000 | 1,297,590,000 | 19,522,000 | 476,431,000 |
Yahoo Snapshot (yfinance, live)
Total Revenue
$274,476,000
EBITDA
$134,447,008
Free Cash Flow
$142,107,376
Enterprise Value
—
Total Cash
$779,404,992
Total Debt
$451,976,992
Shares Out
—
Trailing EPS
—
Book Value
$49.79
ROE
17.1%
ROA
5.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 10y)
Revenues vs Net Income (last 10y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 131,314,000 | 11,942,000 | 52,154,000 | 941,774,000 | 111,335,000 | — | — |
| Dec 2023 | 196,245,000 | 3,037,000 | -33,361,000 | 787,216,000 | 86,303,000 | — | — |
| Dec 2022 | 241,544,000 | 103,851,000 | 57,138,000 | 762,668,000 | 165,183,000 | — | — |
| Dec 2021 | 46,592,000 | -10,144,000 | 18,107,000 | 1,297,590,000 | 476,431,000 | — | — |
| Dec 2020 | 120,282,000 | 807,076,000 | 629,302,000 | 1,362,285,000 | 652,760,000 | — | — |
| Dec 2019 | 43,484,000 | 13,746,000 | 666,337,000 | 1,494,915,000 | 727,683,000 | — | — |
| Dec 2018 | 56,157,000 | 37,041,000 | 45,279,000 | 1,260,803,000 | 699,889,000 | — | — |
| Dec 2017 | 56,157,000 | 37,041,000 | 45,279,000 | 671,021,000 | 252,374,000 | — | — |
| Dec 2016 | 29,648,000 | 15,096,000 | 6,608,000 | 601,585,000 | 230,732,000 | — | — |
| Dec 2015 | 14,602,000 | 3,349,000 | 754,000 | 503,061,000 | 226,151,000 | — | — |
TTM Snapshot
Revenues TTM
$208,736,000
NetIncome TTM
$-3,318,000
OpCashFlow TTM
$0
Assets (Latest)
$941,774,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $949.47B | $1064.74 | — |
| JNJ | JOHNSON & JOHNSON | $554.09B | $230.18 | — |
| ABBV | AbbVie Inc. | $376.54B | $213.12 | — |
| MRK | Merck & Co., Inc. | $295.69B | $119.72 | — |
| AZN | ASTRAZENECA PLC | $290.30B | $187.19 | — |
News headlines (Yahoo Finance, 1h cache)
Is Genpact Stock a Buy After Hedge Fund Rice Hall James Raised Its Stake by $14 Million?
2026-05-19 14:18 · Yahoo
Is WaterBridge Stock a Buy After Ranger Investment Raised Its Stake by 345,000 Shares?
2026-05-16 14:10 · Yahoo
Ligand Pharmaceuticals' (NASDAQ:LGND) Strong Earnings Are Of Good Quality
2026-05-15 12:25 · Yahoo
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
2026-05-12 20:18 · Yahoo
Ligand (LGND) Q1 2026 Earnings Call Transcript
2026-05-12 16:16 · Yahoo
A Look At Ligand Pharmaceuticals (LGND) Valuation After Earnings Miss XOMA Deal And Viking TR-Beta Termination
2026-05-12 11:15 · Yahoo
LGND: 1Q:26 Results Highlight Breadth of Portfolio
2026-05-11 09:32 · Yahoo
Ligand Pharmaceuticals Q1 Earnings Call Highlights
2026-05-08 06:06 · Yahoo
Ligand Reports First Quarter 2026 Financial Results
2026-05-07 11:00 · Yahoo
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
2026-05-06 12:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.